PDCD1 and metastatic melanoma: A multivariate predictive model of response and survival to anti-programmed cell death protein-1 (anti-PD-1) monotherapy or in combination with anti-cytotoxic T-cell lymphocyte-4 (ipilimumab [IPI]; anti-PD-1 + IPI) was developed in metastatic melanoma (76).